Sudoscan in the evaluation and follow-up of patients and carriers with TTR mutations: experience from an Italian Centre.

Marco LuigettiGiulia BisogniAngela RomanoAndrea Di PaolantonioFrancesco BarbatoGiulia PrimicerioPaolo Maria RossiniSerenella ServideiMario Sabatelli

Published in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2019)

We confirmed that Sudoscan is a reliable marker of disease progression in late-onset hATTR amyloidosis patients and we suggest its possible utility in early detection of disease in this population.

Keyphrases

late onset
end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes
patient reported
multiple myeloma